Tyra Biosciences SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company developing FGFR-focused precision medicines. Recent 8-K reports cover operating results, clinical-program updates for TYRA-300/dabogratinib, officer and board appointments, and capital actions under a registered at-the-market offering program.
Proxy materials describe annual meeting voting matters, board structure and corporate-governance procedures. Registration-linked disclosures and material-event reports also identify TYRA common stock, equity issuance activity, and the company’s use of SEC exhibits for press releases and other official corporate records.
Tyra Biosciences, Inc. (TYRA) director Rehan Verjee purchased 971.8943 shares of common stock in an open-market transaction on September 9, 2026 at a weighted average price of $20.5784 per share, with trade prices ranging from $20.5550 to $20.6488. Following this transaction, he holds 971.8943 shares directly. No Rule 10b5-1 trading plan is reported.
Tyra Biosciences, Inc. (TYRA) reported initial Phase 2 data for oral dabogratinib in the SURF302 study in FGFR3‑altered low-grade intermediate-risk non-muscle invasive bladder cancer, providing clinical proof of concept and supporting 60 mg once-daily as a potential dose for a planned registrational adjuvant strategy. As of the August 31, 2026 cutoff, safety and tolerability were favorable in both 60 mg (n=22) and 50 mg (n=22) cohorts, with most treatment-emergent adverse events Grade 1–2; Grade 3 TEAEs occurred in 3 participants (14%) at 60 mg and 2 (9%) at 50 mg, with no Grade 4 or 5 events and no Grade 3 treatment-related events at 60 mg.
Among 26 efficacy-evaluable participants, the 60 mg cohort showed an overall response rate of 79% (11/14) and a best overall complete response rate of 64% (9/14), while the 50 mg cohort showed an overall response rate of 67% (8/12) and complete response rate of 33% (4/12). In single marker lesions, 60 mg achieved a 100% overall response rate (8/8) at three months, and pooled 50/60 mg dosing achieved 94% (15/16). TYRA highlighted that about 61% of enrolled patients had no prior intravesical therapy and cited third-party research estimating a potential IR NMIBC market opportunity of more than $5 billion. TYRA also noted an initial complete response at three months in the first SURF303 low-grade UTUC patient at 60 mg with no observed TEAEs, and clearance of the fifth dose level without safety signals in the BEACH301 pediatric achondroplasia study’s safety sentinel cohort.
TYRA Biosciences, Inc. received an amended Schedule 13G filing reporting the ownership of a Nextech-managed investment vehicle and related parties. Nextech VI Oncology SCSp beneficially owns 3,553,585 shares of TYRA common stock as of June 30, 2026, representing 6.0% of the class, based on 59,470,381 shares outstanding as of May 8, 2026. Nextech VI GP S.a. r.l. is the sole general partner of Nextech VI Oncology SCSp, and Ian Charoub, Costas Constantinides, and Rocco Sgobbo serve on the GP’s board of managers, with power to direct voting and disposition of these shares. The reporting persons expressly disclaim status as a group for ownership reporting purposes.
Tyra Biosciences, Inc. is the subject of an Amendment No. 2 to a Schedule 13G/A filed by a group of Farallon investment entities and individuals. The reporting group, led by Farallon Capital Management, L.L.C. as investment manager, reports beneficial ownership of 6,000 Shares of Tyra’s common stock (CUSIP 90240B106), representing 0% of the class as of June 30, 2026.
The Shares are held across a series of investment partnerships referred to as the Farallon Funds, for which Farallon Capital Management, L.L.C. acts as investment manager. Item 5 indicates the reporting persons now own 5 percent or less of Tyra’s outstanding common stock. The Farallon Funds have the right to receive dividends and sale proceeds from these securities. Multiple Farallon managing members and senior managing members are included as individual reporting persons, with citizenship and organizational details specified.
The issuer of common stock trading under the symbol TYRA is updating its existing at-the-market equity program. An amendment to the sales agreement with TD Securities (USA) LLC (TD Cowen) permits additional issuances of common stock, par value $0.0001 per share, under an at-the-market offering.
The original sales agreement and related prospectus covered up to a maximum aggregate offering price of $150,000,000, all of which has been sold. After giving effect to this prospectus supplement and the amended sales agreement, the issuer may offer and sell up to an aggregate offering price of $250,000,000 of common stock. The common stock is listed on the Nasdaq Global Select Market, where the last reported sale price was $32.04 per share on August 3, 2026.
Tyra Biosciences, Inc., a clinical-stage FGFR-focused biotech, reports continued operating losses as it advances its pipeline. For the three months ended June 30, 2026, net loss was $45.6 million on operating expenses of $49.0 million, including research and development expense of $39.2 million and general and administrative expense of $9.8 million. For the first half of 2026, net loss was $84.9 million on research and development expense of $72.7 million and general and administrative expense of $18.3 million, with no product revenue.
The company highlights progress across oral dabogratinib Phase 2 trials in LG-UTUC (SURF303), IR NMIBC (SURF302) and achondroplasia (BEACH301), plus TYRA-430 in FGF19+ HCC and TYRA-200 in FGFR2-driven ICC. Initial SURF302 results are expected in September 2026, with first BEACH301 and SURF303 readouts anticipated in 2027.
Liquidity remains a key focus: as of June 30, 2026, Tyra held $353.9 million in cash, cash equivalents and marketable securities. It raised $147.9 million in Q1 2026 via an at-the-market offering and subsequently amended that program to permit additional sales of up to $250.0 million, and management believes existing resources will fund operations into the second half of 2028.
Tyra Biosciences, Inc. reported second quarter 2026 results as a clinical-stage biotechnology company focused on FGFR biology. For the quarter ended June 30, 2026, net loss was $45.6 million, with research and development expenses of $39.2 million and general and administrative expenses of $9.8 million. Net loss per share was $0.69 basic and diluted. As of June 30, 2026, cash, cash equivalents and marketable securities totaled $353.9 million.
Management highlighted its “dabogratinib 3x3” strategy, advancing three Phase 2 trials (SURF303 in LG-UTUC, SURF302 in IR NMIBC and BEACH301 in achondroplasia), with initial SURF302 data expected in September 2026 and BEACH301 safety cohort data by end of first quarter 2027. The safety sentinel cohort in BEACH301 has cleared four dose levels without notable safety events, and a fifth dose level has been opened. Tyra appointed Jonathan Day as Executive Vice President, Clinical Development for skeletal dysplasia conditions and amended its at-the-market equity sales agreement, enabling up to an additional $250.0 million in common stock sales. Current cash resources are expected to fund planned operations into the second half of 2028.
BlackRock, Inc. reports a passive ownership stake in TYRA Biosciences, Inc. common stock. BlackRock and certain of its business units beneficially own 2,976,228 shares of TYRA common stock, representing 5.00% of the outstanding class. Of these shares, BlackRock has sole voting power over 2,924,904 shares and sole dispositive power over all 2,976,228 shares, with no shared voting or dispositive power reported. Various underlying clients have economic rights to dividends and sale proceeds, but no single client holds more than five percent of TYRA’s total outstanding common shares.
NEXTECH VI ONCOLOGY SCSP reported sales of TYRA common stock under a Rule 144 notice. The excerpt lists four dispositions in June 2026 with specific trade dates, share quantities, and gross proceeds for each trade. The broker listed is Merrill Lynch.
Tyra Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Stockholders elected three directors: Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More. Each nominee received over 41 million votes in favor, with 8,377,977 broker non-votes recorded on each director item.
Stockholders also approved another meeting proposal with 53,092,820 votes for, 1,316 against, and 3,246 abstentions, and no broker non-votes.